Use of rosiglitazone before and after vascular injury in hypercholesterolemic rabbits: Assessment of neointimal formation

1477-9560-6-12 1477-9560 Original basic research Use of rosiglitazone before and after vascular injury in hypercholesterolemic rabbits: Assessment of neointimal formation Alessi Alexandre acalessi@terra.com.br França Neto Ribeiro Olímpio olimpiofranca@yahoo.com.br Brofman Roberto Slud Paulo mestrado.saude@pucpr.br Prim Camila caprim@terra.com.br Noronha Lucia Inno@terra.com.br Silva Fernando Kuenzer Caetano Ruy rfkcs@bol.com.br Baroncini Andréa Villela Liz lizandreabaroncini@hotmail.com Précoma Bertolim Dalton daltonprecoma@gmail.com

Center of Health and Biological Sciences, Pontifical Catholic University of Paraná, Brazil

Thrombosis Journal 1477-9560 2008 6 1 12 http://www.thrombosisjournal.com/content/6/1/12 18752684 10.1186/1477-9560-6-12 03 6 2008 27 8 2008 27 8 2008 2008 Alessi et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Objectives

To analyse the effects of rosiglitazone administered at different times on neointimal formation in hypercholesterolemic rabbits following vascular injury.

Methods

Thirty-nine rabbits on a hypercholesterolemic diet were included. The animals underwent balloon catheter injury to the right iliac artery on day 14. They were divided into three groups as follows: control group, 13 rabbits without rosiglitazone; group I, 13 rabbits treated with rosiglitazone (3 mg/Kg body weight/day) for 28 days after the vascular injury; and group II, 13 rabbits treated with rosiglitazone (3 mg/Kg body weight/day) during all the experiment (42 days). Histological analysis was done by an experienced pathologist who was unaware of the rosiglitazone treatment. Histomorphometric parameters were performed by calculation of the luminal and intimal layer area, and intima/media layer area ratio (the area of the intimal layer divided by the area of the medial layer).

Results

Intimal area was significantly lower in group II vs. CG (p = 0.024) and group I (p = 0.006). Luminal layer area was higher in group II vs. CG (p < 0.0001) and group I (p < 0.0001). Intima/media layer area ratio was equal between CG and group I. Intima/media layer ratio area was significantly lower in group II vs. control group (p < 0.021) and group I (p < 0.003). There was a significant reduction of 65% and 71% in intima/media layer area ratio in group II vs. control group and group I, respectively.

Conclusion

Pretreatment with rosiglitazone in hypercholesterolemic rabbits submitted to vascular injury significantly reduces neointimal formation.

Introduction

Peroxisome proliferator-activated receptor-γ (PPARγ) has been shown to be expressed in many of the cells that play a role in the response to vascular injury and to modulate the actions that are thought to initiate neointimal (NI) growth, including inflammation 1234. Neointimal formation is an important structural change in the vessel wall that leads to restenosis after angioplasty or stenting 5678.

Thiazolidinediones consist of a family of synthetic compounds that acts as high-affinity ligands for PPARγ and were originally developed to facilitate glucose control in patients with type 2 diabetes. In addition, they have a direct impact on vascular cells and reduce circulating factors that are associated with atherosclerosis 9. In a recent meta-analysis of randomized controlled trials there was evidence that thiazolidinedione therapy in patients undergoing coronary stent implantation may be associated with less in-stent restenosis and repeated revascularization 101112. Three different thiazolidinediones, rosiglitazone, pioglitazone, and troglitazone, have been shown to prevent balloon-injured rat carotid arteries 9. Rosiglitazone can reduce the NI formation and macrophage content in a mouse injury model 1 and in hypercholesterolemic rabbits 2. These effects were independent of glycemic control or changes in lipid concentrations 13. In the present study we analyse the effects of rosiglitazone (RGZ) on neointimal formation administered at different times in hypercholesterolemic rabbits following vascular injury.

Methods

Animals

Thirty-nine white adult male rabbits (New Zealand), weighing 2.474 ± 348 Kg, were utilized for this experiment. Animals were handled in compliance with the Guiding Principles in the Care and Use of Animals. Protocol approval was obtained from the Pontifical Catholic University Animal Research Committee. During first 14 days the animals were fed a hypercholesterolemic diet (1% cholesterol-Sigma-Aldrich^®). Subsequently, they were changed to a 0.5% cholesterol diet until sacrifice (42 days). The animals were divided into three groups as follows: control group (CG) 13 rabbits without RGZ; group I, 13 rabbits treated with RGZ from the fifteenth day (after the vascular injury) until sacrifice; and group II, 13 rabbits treated with RGZ during the entire experiment (42 days). Rosiglitazone was administered by oral gavage (3 mg/Kg body weight/day).

Vascular injury

The rabbits underwent balloon catheter (20 × 3 mm/5 atm/5 min) injury of the right iliac artery on the fourteenth day of the experiment. Anesthesia was induced with ketamine (Vetanarcol^®-König – 3,5 mg/Kg) and intramuscular xylazine (Coopazine^®-Coopers – 5 mg/Kg). After the procedure the animals received intramuscular analgesics for 3 days (25 mg/day of flunixin – Banamine^®– Schering-Plough) and intramuscular antibiotics for 4 days (100 mg/day of oxitetraciclin – TormicinaP^®-Toruga). The rabbits were sacrificed by a lethal barbiturate dose on day 42 and their aorta and iliac arteries were removed for immunohistochemical and histological analysis.

Quantitative histopathology

Histological analysis was performed by an experienced pathologist (LN) unaware of the RGZ treatment. The analyses was done with a microscope attached to the Image Pro-plus^®4.5 Software (Media Cybernetics Inc. Silver Spring, MD. USA). Histomorphometric parameters were performed by calculation of the luminal and intimal layer area, and intima/media layer area ratio (the area of the intimal layer divided by the area of the medial layer) according to the method described by Phillips et al 1. The quantification of total collagen was made by the Sirius red polarization method 14. Atherosclerotic lesions were analysed and classified according to Virmani et al 15.

Immunohistochemistry

Tissue preparation and immunohistological techniques were performed according to the manufacturer's instructions included in the kits (Dako Corporation, Carpinteria, Calif). Sections were stained for macrophage cells using primary monoclonal antibody RAM-11(Dako^®, Carpinteria, CA), and for alpha-actin smooth muscle cells with primary polyclonal antibody HHF-35 (Dako^®, Carpinteria, CA). For quantitative immunocytochemical comparisons of macrophage content or smooth muscle cell content in intimal area, sections were computed and scored in 2 categories based on less than or more than 50% of cells in the balloon injury area.

Blood chemistry

Blood samples were obtained on first day of the experiment, immediately before balloon catheter injury, and immediately before sacrifice by cardiac puncture. Clinical laboratory assessment included fasting serum glucose, total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), and triglycerides (TGC). Measurements were done using an automated system (Abbott Architect ci8200; Abbott Laboratories, Abbott Park, Il).

Statistical analysis

The calculation of sample size was done based on the study of Wang Zhao-hui, Luo Feng and Liu Xiao-mei 16. The ratio between the intimal layer and the media layer was considered to be the main variable of interest. In order to detect a minimum difference of 0.15 between groups averages, with a significance level of 5% and power of the test of 80%, the minimum number of animals in each group of the study was defined as 12. Categorical variables were expressed as percentages and continuous variables were expressed as mean ± SD and medians. Data were compared using Anova one-way. The normality of the samples was tested by using Shapiro-Wilk tests. For non-normal samples, the Kruskal-Wallis and Mann-Whitney non parametric tests were used to compare the groups. Fisher's exact test was used for qualitative or categorical variables. Statistical significance was indicated by a value of p < 0.05. Analyses were performed using SPSS version 14.0 (SPSS, Inc., Chicago, Illinois).

Results

Metabolic and lipid profiles

The rabbit's weight did not differ between groups (data not shown). Baselineglucose, total cholesterol, HDL-cholesterol and triglycerides levels were equal in all groups before initiation of the diet. On day 14, two weeks after feeding, fasting glucose levels were higher in CG and group I. At the time of sacrifice glucose levels did not differ between groups. A graded elevation in TC and TGC levels was observed from the initial phase through the vascular lesion until sacrifice without significant differences between groups. A graded elevation in HDL-C was observed in all three groups. Higher levels of HDL-C were observed in group II versus CG and group I at the time of vascular injury and sacrifice (Table 1).

Table 1

Metabolic and lipid profiles (mean ± SD)

Group I

Group II

P value

Baseline

TC (mg/dl)

58.62 ± 25.08

50.77 ± 18.39

43.54 ± 14.82

HDL-C (mg/dl)

24.23 ± 5.31

23.1 ± 6.12

22.69 ± 6.26

NS *

TGC (mg/dl)

79.62 ± 26.64

91.15 ± 32.71

79.85 ± 34.31

NS *

Glucose (mg/dl)

121.38 ± 17.43

120.77 ± 19.07

117.92 ± 11.44

Vascular injury

TC (mg/dl)

524.38 ± 258.94

431.77 ± 197.38

318.46 ± 212.86

HDL-C (mg/dl)

32.46 ± 19.66

28.77 ± 6.15

50.69 ± 21.91

NS *

TGC (mg/dl)

72.77 ± 34.95

71.54 ± 46.54

86.92 ± 56.34

NS *

Glucose (mg/dl)

250.23 ± 93.02

274.46 ± 58.45

166.62 ± 38.2

0.001

Sacrifice

TC (mg/dl)

852.46 ± 308.48

702.62 ± 261.53

593.54 ± 219,86

HDL-C (mg/dl)

42.62 ± 38.23

25.08 ± 13.93

69.08 ± 19.7

0,001 *

TGC (mg/dl)

126.77 ± 85.66

398.08 ± 509.76

277.31 ± 248.14

NS *

Glucose (mg/dl)

212.85 ± 73.71

210.92 ± 72.99

233.85 ± 89.65

NS – non significant.

* Kruskal-Wallis

Histomorphometry

Intimal area was significantly lower in group II vs. CG (p = 0.024) and group I (p = 0.006). Luminal layer area was higher in group II vs. CG (p < 0.0001) and group I (p < 0.0001). There was a significant reduction of 65% and 71% in intima/media layer area ratio (IMR) in group II vs. CG (p = 0.021) and vs. group I (p = 0.003), respectively. Intima/media layer area ratio was equal between CG and group I. (Table 2). (Figures 1 and 2). According to the histological analysis proposed by Virmani et al, none of the criteria from1 trough 9 were found in group II, therefore the comparisons were only made between CG and group I. Neointimal growth, xanthomatous macrophages, proteoglican matrix, the presence and the thickness of fibrous cap, and the presence of calcification did not differ between CG and group I. There was no deposit of collagen into intimal or medial layers in group II, nor were there differences in the extent of collagen deposition between CG and group I. (Table 3).

Figure 1

Representative histological sections demonstrating neointimal formation – Orcein Staining

Representative histological sections demonstrating neointimal formation – Orcein Staining.Panel A: Control group. Panel B: Group I. Panel C: Group II. NI represents neointima.

Figure 2

Quantification of intima/media layer area ratio; and total intimal layer area

Quantification of intima/media layer area ratio; and total intimal layer area.

Table 2

Quantitative histopathological analysis

Area

Group

Mean

Minimum

Maximum

Intimal area

320340.22

392880.74

14720.20

1512612.11

0.024

282659.14

346471.14

14500.40

1361362.80

0.006

GII

83115.01

65440.66

16187.50

269226.60

Luminal area

458711.01

363013.82

1853.54

1773080.00

<0.0001

556450.31

330540.15

3274.59

1486461.00

<0.0001

GII

861255.24

303153.71

222741.70

1586336.00

IMR

0.50

0.41

0.04

1.13

0.021

0.59

0.36

0.08

1.36

0.003

GII

0.18

0.14

0.03

0.49

IMR represents intima/media area ratio. Area was estimated in square micrometer.

Table 3

Qualitative histopathology between CG and Group I

Presence

Group I

p value

Intimal thickening (%)

30.76

15.38

> 0.05

Yes

69.23

84.61

> 0.05

Isolated Xanthomamacrophages (%)

30.76

15.38

> 0.05

Yes

69.23

84.61

> 0.05

Agregate Xanthomamacrophages (%)

38.46

15.38

> 0.05

Yes

61.53

84.61

> 0.05

Lipid drops of proteoglican matrix (%)

38.46

15.38

> 0.05

Yes

61.53

84.61

> 0.05

Lipid lakes of proteoglican matrix (%)

38.46

30.76

> 0.05

Yes

61.53

69.23

> 0.05

Thin fibrous cap atheroma (%)

84.61

92.30

> 0.05

Yes

15.38

7.69

> 0.05

Calcified nodule (%)

53.84

15.38

> 0.05

Yes

46.15

84.61

> 0.05

Calcification (%)

92.30

76.92

> 0.05

Yes

7.69

23.07

> 0.05

Collagen Type I (mean ± sd)

880.9 ± 436.5

264.5 ± 104.04

0.29

Collagen Type III (mean ± sd)

680.5 ± 267.54

312.24 ± 98.89

0.41

No represents less than 50% of cells in the balloon injury area. Yes represents more than 50% of cells in the balloon injury area.

Immunohistochemistry

There was no significant difference in macrophage and smooth muscle cell content in the intimal layer between CG and group I (data not show). Group II did not present any intimal cell markers.

Discussion

Prevention of restenosis after balloon coronary angioplasty or stent implantation with the use of local and systemic therapy is a challenging issue in interventional cardiology 417181920. Osborne et al 21 showed that a short term model of hypercholesterolemia (two to four weeks) prevents extremely high cholesterol values and formation of advanced atherosclerotic plaques. Nevertheless, the arteries isolated from animals fed a cholesterol-enriched diet developed defects in endothelium-dependent relaxation in both large vessels as well as coronary resistance vessels 22. These effects could be, in part, responsible for the restenosis after balloon angioplasty. Thiazolidinediones have immunomodulatory and antiproliferative effects, independent of their actions in metabolic control and are expressed in most cell types of the vascular wall as in atherosclerotic lesions, where they can affect atherogenic process 2324252627282930. To investigate the effects of a PPARγ ligand (rosiglitazone) on atherogenesis in an animal model, we used rabbits with six-fold increased cholesterol levels at the time of vascular injury and fourteen-fold increased levels at the time of euthanasia. This animal model was based on previous studies where rabbits develop hypercholesterolemia rapidly after excessive cholesterol feeding 232224. The metabolic effects of high cholesterol-containing diet on rabbits were extensively explained in our previous study 31. Rosiglitazone was used at different times for each group. Group II not only did not present atherosclerotic lesions but also did not show any deposit of collagen or macrophage and smooth muscle cell markers in their intimal layer. The most significant findings were identified in the higher luminal area and the lower intimal area in which rabbits were treated with RGZ before vascular injury. Furthermore, in CG and group I intense reparative response occurred, with exuberant neointimal formation and reduction of luminal area. In addition, immunohistochemical analysis demonstrated a reduced macrophage and smooth muscle cell recruitment into the vascular arterial wall when RGZ was used two weeks before catheter balloon injury. Rosiglitazone did not exert anti-atherosclerotic activity when administered after vascular injury, however, a lesser density of macrophages in the media layer was observed in the animals of group I. We cannot rule out that these effects were due to chance, as our evaluation period was short. These findings suggest a possible protective effect of this drug against neointimal proliferation and remodeling responsible for restenosis after a balloon angioplasty. This is the first study to show the effects of a PPARγ ligand on vascular injury at different times and to document the benefits of pre-treatment with RGZ in hypercholesterolemic rabbits. Nevertheless, this drug has been the focus of extensive discussion in recent publications 323334353637. Nissen and Wolski 32 published a meta-analysis showing a significant increase in the risk of myocardial infarction and an increase in cardiovascular death of borderline significance in patients with diabetes receiving RGZ. Singh et al 33 also published a meta-analysis showing a significantly increased risk of myocardial infarction and heart failure among patients with impaired glucose tolerance or type 2 diabetes using rosiglitazone for at least 12 months, with no significantly increased risk of cardiovascular mortality. Lipscombe et al 34, in a nested case-control analysis of a retrospective cohort study, found that in diabetes patients with an age of 66 years or older, RGZ treatment was associated with an increased risk of congestive heart failure, acute myocardial infarction, and mortality when compared with other combination oral hypoglycemic agent treatments. The mechanism for the apparent increase in myocardial infarction and death from cardiovascular causes associated with RGZ remains uncertain. In the PERISCOPE randomized controlled trial 37, using coronary intravascular ultrasonography, the authors found a significantly lower rate of progression of coronary atherosclerosis in patients treated with pioglitazone when compared with glimiperide. However, it is not possible to extend the positive or negative benefit of one drug to another in the same class. In the next three years, we hope that the final results of the studies RECORD and BARI-2D 38, specifically evaluating cardiovascular effects of RGZ, will provide useful insights.

Conclusion

The results of our study indicate that when rosiglitazone is administered in hypercholesterolemic rabbits before, but not after, undergoing vascular injury, there is significantly reduced neointimal formation.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

AA participated in the study design, ORFN participated in the study design, PRSB oriented in the surgical procedures, CP oriented in the management of the animals, LN made the histological examination, RFKCS oriented in the surgical procedures, LAVB wrote and oriented the manuscript, DBP participated in the study design. All authors read and approved the final manuscript.

Rosiglitazone reduces the accelerated neointima formation after arterial injury in a mouse injury model of type 2 diabetes Phillips JW Barringhaus KG Sanders JM Yang Z Chen M Hesselbacher S Czarnik AC Ley K Nadler J Sarembock IJ Circulation 2003 108 1994 1999 10.1161/01.CIR.0000092886.52404.50 14517165 A potent activator of PPARα and γ reduces the vascular cell recruitment and inhibits the intimal thickning in hypercholesterolemic rabbits Seki N Bujo H Jiang M Shibasaki M Takahashi K Hashimoto N Saito Y Atherosclerosis 2005 178 1 7 10.1016/j.atherosclerosis.2004.08.015 15585194 Rosiglitasone attenuates atherosclerosis in a model of insulin insufficiency independent of its metabolic effects Calkin AC Forbes JM Smith CM Lassila M Cooper ME Jandeleit-Dahm KA Allen TJ Arterioscler Thromb Vasc Biol 2005 25 1903 1909 10.1161/01.ATV.0000177813.99577.6b 16020748 Vascular effects of TZDs: New implications Blaschke F Spanheimer R Khan M Law RE Vascular Pharmacology 2006 45 3 18 10.1016/j.vph.2005.11.009 16740417 Different response to balloon angioplasty of carotid and coronary arteries: Effects on acute platelet deposition and intimal thickening Badimon JJ Fernadez-Ortiz A Meyer B Mailhac A Fallon JT Falk E Badimon L Chesebro JH Fuster V Atherosclerosis 1998 140 307 314 10.1016/S0021-9150(98)00134-8 9862273 Vascular injury, repair and restenosis after percutaneos transluminal angioplasty in the atherosclerotic rabbit Wilenski RL March KL Gradus-Pizlo I Sandusky G Fineberg N Hathway DR Circulation 1995 92 2995 3005 7586270 Inhibition of atherosclerosis by fish oil in cholesterol-fed rabbits Zhu BQ Smith DL Sievers RE Isemberg WM Parmley WW J AM Coll Cardiol 1988 12 1073 1078 3417980 The patogenesis of atherosclerosis: a perspective for 1990s Ross R Nature 1993 362 801 809 10.1038/362801a0 8479518 PPARγ and atherosclerosis. Effects on cell growth and movement Hsueh WA Law RE Arterioscler Thromb Vasc Biol 2001 21 1891 1895 10.1161/hq1201.100261 11742860 Effect of thiazolidinedione therapy on restenosis after coronary stent implantation: A meta-analysis of randomized controlled trials Rosmarakis ES Falagas ME Am Heart J 2007 154 144 50 10.1016/j.ahj.2007.04.005 17584567 Peroxisome proliferator-activated receptor γ agonists for the prevention of adverse events following percutaneous coronary revascularization-results of the PPAR study Bhatt DL Chew DP Grines C Mukherjee D Leesar M Gilchrist IC Corbelli JC Blankenship JC Eres A Steinhubl S Tan WA Resar JR AlMahameed A Abdel-Latif A Tang HW Brennan D McErlean E Hazen SL Topol EJ Am Heart J 2007 154 137 43 10.1016/j.ahj.2007.03.029 17584566 Thiazolidinediones and risk of repeat target vessel revascularization following percutaneous coronary intervention Riche DM Valderrama R Henyan NN Diabetes Care 2007 30 384 388 10.2337/dc06-1854 17259517 Pioglitazone reduces smooth muscle cell density of rat carotid arterial intima induced by balloon catheterization Igarashi M Takeda Y Ishibashi N Takahashi K Mori S Tominaga M Saito Y Horm Metab Res 1997 29 9 444 449 9370113 Quantification of total collagen in rabbit tendon by the Sirius red method Taskiran D Taskiran E Yercan H Kutay FZ Tr J of Medical Scienses 1999 29 7 9 Lessons from sudden coronary death. A comprehensive morphological classification scheme for atherosclerotic lesions Virmani R Kolodgie FD Burke AP Farb A Schwartz SM Arterioscler Thromb Vasc Bio 2000 20 1262 1275 Effect of PPARgamma agonist rosiglitazone on regression of the atherosclerotic plaques in rabbits Wang ZH Luo F Liu XM Yao Xue Xue Bao 2005 40 11 1051 3 16499094 Vascular restenosis: Basic science and clinical implications Heckencamp J Gawenda M Brunkwall J J Cardiovasc Surg (Torino) 2002 43 3 349 357 12055567 Prevention of restenosis by systemic drug therapy: back to the future Schomig A Kastrati A Wessely R Circulation 2005 112 2759 2761 10.1161/CIRCULATIONAHA.105.583484 16267248 Pathophysiology of Coronary Artery Restenosis Schwartz RS Henry TD Rev Cardiovasc Med 2002 3 Suppl 5 S4 9 12478229 Troglitazone reduces neointimal tissue proliferation after coronary stent implantantion in patients with non-insulin dependent diabetes mellitus: a serial intravascular ultrasound study Takagi T Akasaka T Yamauchi M J Am Coll Cardiol 2000 36 1529 1535 10.1016/S0735-1097(00)00895-0 11079654 Cardiovascular effects of acute hypercholesterolemia in rabbits. Reversal with lovastatin treatment Osborne JA Lento PH Siegfried MR Stahl GL Fusman B Lefer AM J Clin Invest 1989 83 465 473 303702 2913050 10.1172/JCI113905 Effects of cholesterol diets on vascular function and atherogenesis in rabbits Sun YP Lu NC Parmililitrosey WW Hollenbeck CB Diets, Vascular Finction, and Atherogenesis 2000 224 166 171 Effects of peroxisome proliferator-activated receptor ligands in modulating tissue-factor and tissue-factor pathway inhibitor in acutely symptomatic carotid atheromas Golledge J Mangan S Clancy P Stroke 2007 38 1501 1507 10.1161/STROKEAHA.106.474791 17363721 Anti-apoptotic effects of rosiglitazone in hypercholesterolemic rabbits subjected to myocardial ischemia and reperfusion Liu HR Tao L Gao E Lopez BL Christopher TA Willette RN Ohlstein EH Yue TL Ma XL Cardiovascular research 2004 62 135 144 10.1016/j.cardiores.2003.12.027 15023560 PPAR gamma dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation Chawla A Barak Y Nagy L Liao D Tontonoz P Evans RM Nat Med 2001 7 48 52 10.1038/83336 11135615 Preventive effects of rosiglitazone on restenosis after coronary stent implantation in patients with type 2 diabetes Choi D Kim SK Choi SH Ko YG Ahn CW Jang Y Lim SK Lee HC Cha BS Diabetes Care 2004 27 2654 2660 10.2337/diacare.27.11.2654 15505001 Troglitazone inhibits formation of early atherosclerotic lesions in diabetic and non-diabetic low density lipoprotein receptor-deficient mice Collins AR Meehan WP Kintscher U Jackson S Wakino S Noh G Palinski W Hsueh WA Law RE Atheroscler Thromb Vasc Biol 2001 21 365 371 Secundary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomized controlled trial Dormandy JA for the PROactive investigators Lancet 2005 366 279 1289 10.1016/S0140-6736(05)67528-9 16044531 Effect of peroxisome proliferator-activated receptor γ agonist treatment on subclinical atherosclerosis in patients with insulin-requiring type 2 diabetes Hodis HN Mack WJ Zheng L Li Y Torres M Sevilla D Stewart Y Hollen B Garcia K Alaupovic P Buchanan TA Diabetes Care 2006 29 1545 1553 10.2337/dc05-2462 16801577 Control of vascular cell proliferation and migration by PPAR gamma Hsueh WA Jackson S Law RE Diabetes Care 2001 24 392 397 10.2337/diacare.24.2.392 11213897 Effects of rosiglitazone on contralateral iliac artery after vascular injury in hypercholesterolemic rabbits França Neto OR Précoma DB Alessi A Prim C Silva RFKC Noronha L Baroncini LAV Thromb J 2008 6 4 18485218 2396603 10.1186/1477-9560-6-4 Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes Nissen SE Wolski K N Engl J Med 2007 356 2457 2471 10.1056/NEJMoa072761 17517853 Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis Singh S Loke YH Furberg CD JAMA 2007 298 1216 8 10.1001/jama.298.10.1216 17848659 Thiazolidinediones and cardiovascular outcomes in older patients with diabetes Lipscombe LL Gomes T Lévesque LE Hux JE Juurlink DN Alter DA JAMA 2007 298 10 1189 95 10.1001/jama.298.10.1189 17848653 Thiazolidinediones and risk for atherosclerosis: pleitropic effects of PPARγ agonism Patel CB De Lemos JA Wyne KL Mcguire DK Diabetes Vasc Dis Res 2006 3 65 71 10.3132/dvdr.2006.016 Rosiglitazone evaluated for cardiovascular outcomes – an interim analysis Home PD Pocock SJ Beckk-Nielsen H Gomis R Hanefeld M Joses NP Komajda M McMurray JJV for the Record Study Group N Engl J Med 2007 357 28 38 10.1056/NEJMoa073394 17551159 Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes. The PERISCOPE randomized controlled trial Nissen SE Nicholls SJ Wolski K Nesto R Kupfer S Perez A Jure H De Larochellière R Staniloae CS Mavromatis K Saw J Hu B Lincoff AM Tuzcu EM JAMA 2008 299 1561 1573 10.1001/jama.299.13.1561 18378631 Pleiotropic actions of peroxisome proliferator-activated receptors in lipid metabolism and atherosclerosis Barbier O Torra IP Duguay Y Blanquart C Fruchart JC Glineur C Staels B Arterioscler Thromb Vasc Bio 2002 22 717 726 10.1161/01.ATV.0000015598.86369.04